Palliative Care: Research and Treatment 2014:8 7-10
Review
Published on 11 May 2014
DOI: 10.4137/PCRT.S13489
Sign up for email alerts to receive notifications of new articles published in Palliative Care: Research and Treatment
Levorphanol (levo-3-hydroxy-N-methylmorphinan) is a step 3 opioid first developed in the 1940s as an alternative to morphine. Levorphanol belongs to the morphinan opioid series. Levorphanol has greater potency than morphine and is a potent N-methyl-D aspartate (NMDA) antagonist. Levorphanol interferes with the uptake of norepinephrine and serotonin, which makes it potentially useful for neuropathic pain. Glucuronidation changes Levorphanol to Levorphanol-3-glucuronide with excretion by the kidney. Levorphanol has a long half-life and may accumulate with repeated dosing. Levorphanol can be administered orally, intravenously, and subcutaneously. This article provides an update regarding the pharmacodynamics, pharmacology, and clinical efficacy of this often overlooked step 3 opioid.
PDF (749.65 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
PMC HTML
This is the second time I have submitted a paper to Palliative Care: Research and Treatment for possible publication. In both instances, my experience with Libertas Academica was very good from submission to acceptance. The peer reviewers' comments were insightful, very constructive, and extremely helpful. The author interface was user-friendly. The publishing process was fast and convenient. I highly recommend this journal.
Facebook Google+ Twitter
Pinterest Tumblr YouTube